Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)Yosuke Kawashima, Hiroshi Kagamu, Toshiyuki Kozuki et al.|Annals of Oncology|2019Cited by 0